PK/PD Studies

With 25 years of experience, Lambda Therapeutic Research offers unmatched expertise in early-phase development and has successfully completed more than 8,000 PK/PD studies. Our dedicated team of global experts in early-phase development and clinical pharmacology carefully designs integrated programs that meet the highest standards. We conduct a wide range of studies, including first-in-human (FIH), proof-of-concept, bioavailability and bioequivalence (BA/BE), drug-drug interaction (DDI), biosimilar, pharmacokinetic (PK), and single ascending dose/multiple ascending dose (SAD/MAD) studies.

We operate over 700 clinical beds, including more than 85 specialized beds for complex bioequivalence studies. Our services cover every aspect of early-phase research, from clinical conduct and monitoring to bioanalysis and project management, all fully aligned with global regulatory requirements.